Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Prostate Cancer

Presenters

Paolo Tralongo

Citation

Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248

Authors

P. Tralongo1, S. Bordonaro1, G. Di Lorenzo2, N. Borsellino3, G. Facchini4, S. Rossetti4, V. Martelli5, V. Longo6, A.C. Tralongo7, F. Caspani7, A. Tuzi7, M. Spada8, N. Calvani9, P. Carlini10, U.F.F. De Giorgi11

Author affiliations

  • 1 Oncology Unit, Umberto I Hospital (Siracusa), 96100 - Siracusa/IT
  • 2 Oncologia Medica, University Federico II of Naples, 80131 - Napoli/IT
  • 3 Oncology Unit, Ospedali Buccheri la Ferla, 90144 - Palermo/IT
  • 4 Uro-gynaecologic, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 5 Oncologia Medica 1, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 6 Medical Thoracic Oncology Unit, Irccs Istituto Tumori "giovanni Paolo Ii", Bari,, Istituto Tumori Giovanni Paolo II, 70126 - Bari/IT
  • 7 Medical Oncology, University of Insubria-Ospedale del Circolo, 21100 - Varese/IT
  • 8 Oncology Unit, Fondazione Istituto San Raffaele - G. Giglio di Cefalù, 90015 - Cefalù/IT
  • 9 Oncology Unit, Ospedale A. Perrino, 72100 - Brindisi/IT
  • 10 Dipartimento Clinico Sperimentale Oncologico, Istituto Nazionale Tumori Regina Elena, 00144 - Rome/IT
  • 11 Medical Oncology Department, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3524

Background

Cabazitaxel (CAB) was marketed in 2012 in Italy, based on overall survival (OS) benefit demonstrated on the TROPIC study in mCRPC post-docetaxel. The efficacy and tolerability of CAB is overlapping in all age groups, though for very elderly patients (pts) it has never really been verified.

Methods

We conducted a retrospective, observational real-life study in 57 octogenarian pts, treated with CAB in eleven Italian cancer centers from 2012 to 2018. Feasibility of treatment has been investigated by duration of treatment and its tolerability. Duration of treatment and toxicity profile were also evaluated according to

Results

This retrospective cohort included 57 mCRPC pts (median age 83.5 years; 21% aged over 85 years), 24% with exclusive bone metastatic disease, 50% with high-volume bone disease, 15% with high volume bone disease and visceral disease. Thirty-nine (68%) received the CGA questionnaire assessment, 34 resulted fit and 5 vulnerable. Ten (14%) had an ECOG PS ≥ 2, 9% received CAB as second-line, 23 (40%) as third-line, 29 (51%) as forth or more line. CAB was administered at 25 mg/sqm in 30 (52%) pts, and 20 mg/sqm or adapted schedules in 27 (48%). These latter schedules were adopted mainly in the subgroups with age > 85 years (75%), PS ≥ 2 (87.5%) and vulnerable according CGA questionnaires (100%). The median duration of treatment with CAB in all pts was 4.8 months, range 1-19 months (mo); 4.5 mo in those aged > 85 years, 4.4 mo in the vulnerable pts and 3.5 mo in pts with PS ≥ 2. The most represented grade 3-4 toxicity in the whole cohort were neutropenia (14%) and diarrhea (10.5%). Six patients (10.5%) drop out the treatment for significant toxicities: 3 febrile neutropenia G4, 2 diarrhea G4 and 1 severe cardiotoxicity, 5 (83%) of these pts received the 25 mg/sqm schedule, and 4 pts (67%) aged between 80-84 yeras with ECOG PS = 0 did not performed the CGA assessment before treatment. One death due to intestinal perforation non-clearly treatment-related was reported.

Conclusions

Octogenarian patients may be treated with CAB with the 20 mg/sqm regimen associated with less treatment interruptions. The CGA could contribute to better select pts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.